Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug74 | 5Fluorouracil Wiki | 0.58 |
drug2301 | Laboratory Biomarker Analysis Wiki | 0.58 |
drug1350 | Docetaxel Wiki | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
drug1604 | F-FMISO PET/CT Scan Wiki | 0.58 |
drug583 | Berzosertib Wiki | 0.58 |
drug3425 | Proton Therapy Wiki | 0.58 |
drug994 | Cisplatin Wiki | 0.58 |
drug58 | 30 Gy over 3 weeks Wiki | 0.58 |
drug1523 | Entinostat Wiki | 0.58 |
drug1104 | Conjunctival swab and nasopharyngeal swab Wiki | 0.58 |
drug411 | Atezolizumab Wiki | 0.41 |
drug1133 | Convalescent COVID 19 Plasma Wiki | 0.41 |
drug1546 | Etoposide Wiki | 0.41 |
drug3386 | Probiotic Wiki | 0.33 |
drug1116 | Control Wiki | 0.15 |
Name (Synonyms) | Correlation | |
---|---|---|
D002294 | Carcinoma, Squamous Cell NIH | 0.41 |
D018288 | Carcinoma, Small Cell NIH | 0.41 |
D002277 | Carcinoma NIH | 0.35 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002860 | Squamous cell carcinoma HPO | 0.41 |
HP:0030731 | Carcinoma HPO | 0.35 |
HP:0030357 | Small cell lung carcinoma HPO | 0.33 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012125 | Prostate cancer HPO | 0.24 |
HP:0002664 | Neoplasm HPO | 0.08 |
Navigate: Correlations HPO
There are 3 clinical trials
The purpose of this study is to demonstrate that participants with HPV positive and hypoxia negative T1-2, N1-2c (AJCC, 7th ed.) oropharyngeal squamous cell carcinoma receiving a major de-escalated radiation therapy with 2 cycles of standard chemotherapy is not inferior to comparable subjects treated with the current standard chemoradiation. Given the restrictions of surgery during the COVID19 pandemic, we will start enrolling patients on Cohort B where surgery is not required. Once the COVI19 pandemic is over, we will resume and complete enrollment on Cohort A where surgery is required, prior to continuing enrolling patients on Cohort B. During the COVID-19 pandemic, the research MRIs are optional.
This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving M6620, carboplatin and docetaxel may work better in treating patients with metastatic castration-resistant prostate cancer compared to carboplatin and docetaxel alone.
Description: Defined by radiographic response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or prostate specific antigen [PSA] response of > 50%). Will be conducted using the Cochran-Mantel-Haenszel test, with one-sided p-value of =< 0.05 considered significant.
Measure: Response rate (complete response + partial response) Time: Up to 2 yearsDescription: Assessed by Prostate Cancer Working Group (PCWG)3. PFS to be estimated with the Kaplan Meier methodology. Median and event-free rate at selected time points will be provided with 95% confidence interval.
Measure: Progression-free survival (PFS) Time: From the time of randomization up to 2 yearsDescription: Assessed by PCWG2. PSA progression will be estimated with the Kaplan Meier methodology. Median and event-free rate at selected time points will be provided with 95% confidence interval. Comparison of time to PSA progression between arms will be conducted using the log-rank test.
Measure: Time to PSA progression Time: From the time of randomization up to 2 yearsDescription: Assessed by RECIST 1.1. rPFS will be estimated with the Kaplan Meier methodology. Median and event-free rate at selected time points will be provided with 95% confidence interval.
Measure: Radiographic progression-free survival (rPFS) Time: From the time of randomization up to 2 yearsDescription: Will be summarized according to treatment arm. For toxicity reporting, all adverse events will be graded and analyzed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Type of adverse events, intensity (grading), and attribution will be provided in a listing. All adverse events resulting in discontinuation, dose modification, and/or dosing interruption, and/or treatment delay of drug will also be summarized. Laboratory test results will be classified according to the CTCAE version 5.0.
Measure: Incidence of adverse events Time: Up to 2 yearsDescription: OS will be estimated with the Kaplan Meier methodology. Comparison of OS between arms will be conducted using the log-rank test base on the intention-to-treat approach, where two treatment arms will be compared regardless of cross-over or any subsequent therapy.
Measure: Overall survival (OS) Time: From the time of randomization up to 2 yearsDescription: Gene mutation frequencies and mean +/- standard deviation of quantitative biomarkers will be summarized by arm and in overall population at baseline and/or at end of study.
Measure: Gene mutation frequencies Time: Baseline up to 2 yearsThis phase I trial identifies the best dose and side effects of entinostat in combination with atezolizumab, carboplatin and etoposide for the treatment of previously untreated aggressive lung cancer that has spread (extensive-stage small cell lung cancer). Entinostat and etoposide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving entinostat in combination with atezolizumab, carboplatin and etoposide may work better than atezolizumab, carboplatin and etoposide alone.
Description: The Bayesian optimal interval (BOIN) design will be used to find the MTD based on safety.
Measure: Maximum tolerated dose (MTD) Time: Up to 21 daysDescription: Defined by Common Terminology Criteria for Adverse Events version 5.0. Will be summarized by frequency and magnitude.
Measure: Grade 3/4 adverse event rate Time: Up to 30 daysDescription: The proportion of participants who receive 3 or more cycles of the combination, will be calculated with a 90% confidence interval.
Measure: Number of cycles received of the combination of entinostat, atezolizumab, carboplatin, and etoposide Time: Up to cycle 4 (1 cycle = 21 days)Description: Defined as the proportion of patients alive and without disease progression after 9 months from study enrollment. The 9 month PFS rate will be estimated with a 90% confidence interval. The Kaplan Meier estimator will be used to estimate survival curves.
Measure: 9-month progression free survival (PFS) rate Time: 9 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports